ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

19 links1 made here, not in the record34 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule basedMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT03297606Canadian Profiling andTargeted Agent UtilizationTrial (CAPTUR)Canadian Cancer Trials GroupPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSLymphoma, Non-HodgkinThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionMultiple MyelomaThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSOlaparibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDasatinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedNivolumabEntry “Nivolumab plus Ipilimumab”, re…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedIpilimumabEntry “Nivolumab plus Ipilimumab”, re…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAxitinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedBosutinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCrizotinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPalbociclibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedSunitinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTemsirolimusIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedErlotinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrastuzumabEntry “Trastuzumab plus Pertuzumab”, …›Nov 2 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionPertuzumabEntry “Trastuzumab plus Pertuzumab”, …›Nov 2 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionINT010011Entry “Vemurafenib plus Cobimetinib”,…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedHhAntag691Entry “Vismodegib”, read by our name …›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTucatinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCobimetinibMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Olaparib

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Olaparib”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2OlaparibClaude Opus 5.5TestedCurrent
Nov 2DasatinibClaude Opus 5.5TestedCurrent
Nov 2NivolumabClaude Opus 5.5TestedCurrent
Nov 2IpilimumabClaude Opus 5.5TestedCurrent
Nov 2AxitinibClaude Opus 5.5TestedCurrent
Nov 2BosutinibClaude Opus 5.5TestedCurrent
Nov 2CrizotinibClaude Opus 5.5TestedCurrent
Nov 2PalbociclibClaude Opus 5.5TestedCurrent
Nov 2SunitinibClaude Opus 5.5TestedCurrent
Nov 2TemsirolimusClaude Opus 5.5TestedCurrent
Nov 2ErlotinibClaude Opus 5.5TestedCurrent
Nov 2TrastuzumabClaude Opus 5.5Background · optionCurrent
Nov 2PertuzumabClaude Opus 5.5Background · optionCurrent
Nov 2INT010011Claude Opus 5.5TestedCurrent
Nov 2HhAntag691Claude Opus 5.5TestedCurrent
Nov 2TucatinibClaude Opus 5.5TestedCurrent
Nov 2Cobimetinibmade hereClaude Opus 5.5TestedCurrent
Nov 18OlaparibRule based · role ruleTestedAgrees
Nov 18DasatinibRule based · role ruleTestedAgrees
Nov 18NivolumabRule based · role ruleTestedAgrees
Nov 18IpilimumabRule based · role ruleTestedAgrees
Nov 18AxitinibRule based · role ruleTestedAgrees
Nov 18BosutinibRule based · role ruleTestedAgrees
Nov 18CrizotinibRule based · role ruleTestedAgrees
Nov 18PalbociclibRule based · role ruleTestedAgrees
Nov 18SunitinibRule based · role ruleTestedAgrees
Nov 18TemsirolimusRule based · role ruleTestedAgrees
Nov 18ErlotinibRule based · role ruleTestedAgrees
Nov 18TrastuzumabRule based · role ruleTestedOverridden
Nov 18PertuzumabRule based · role ruleTestedOverridden
Nov 18INT010011Rule based · role ruleTestedAgrees
Nov 18HhAntag691Rule based · role ruleTestedAgrees
Nov 18TucatinibRule based · role ruleTestedAgrees
As of nowLymphoma, Non-HodgkinRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.